Tonghua Golden-Horse Pharmaceutical Industry CoLtd 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Hongjun Zhan

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	4.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	18.3yrs
이사회 평균 재임 기간	4.6yrs

최근 관리 업데이트

Recent updates

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd's (SZSE:000766) Popularity With Investors Is Under Threat From Overpricing

Aug 20

Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) Seems To Use Debt Quite Sensibly

Jun 03

Should You Be Adding Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) To Your Watchlist Today?

May 12

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SZSE:000766) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Mar 06

CEO

Hongjun Zhan (54 yo)

4.3yrs

테뉴어

CN¥960,000

보상

Mr. Hongjun Zhan is General Manager of Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd from August 19, 2020. He served as Non-Independent Director of Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd...

리더십 팀

이름	위치	테뉴어	보상	소유권
Hongjun Zhan	General Manager	4.3yrs	CN¥960.00k	데이터 없음
Yu Jun	Deputy GM & CFO	18.3yrs	CN¥600.00k	데이터 없음
Yu Jing	Deputy GM & Non-Independent Director	no data	CN¥600.00k	데이터 없음
Weilin Jia	Secretary & Deputy GM	22.4yrs	CN¥480.00k	데이터 없음

18.3yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 관리: 000766 의 관리팀은 노련하고 경험 (평균 재직 기간 18.3 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yu Jing	Deputy GM & Non-Independent Director	1.3yrs	CN¥600.00k	데이터 없음
Xu Changyou	Chairman of the Supervisory Board	13.4yrs	데이터 없음	데이터 없음
Qibin Chen	Independent Director	6.5yrs	CN¥50.40k	데이터 없음
Yufu Zhang	Chairman	5.2yrs	CN¥900.00k	데이터 없음
Huan Wang	Non-Independent Director	5.2yrs	CN¥420.00k	데이터 없음
Yingjie Wei	Non-Independent Director	4.6yrs	데이터 없음	0.019% CN¥ 2.6m
Qiang Zhou	Non-Independent Director	4.6yrs	데이터 없음	데이터 없음
Guixia Lv	Independent Director	4.6yrs	CN¥50.40k	데이터 없음
Qiuting Yin	Supervisor	4.6yrs	데이터 없음	데이터 없음
Jindi Guo	Supervisor	4.6yrs	데이터 없음	데이터 없음
Haoyan Zhang	Non-Independent Director	1.3yrs	데이터 없음	데이터 없음
Jiajun Han	Independent Director	1.3yrs	데이터 없음	데이터 없음

4.6yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 이사회: 000766 의 이사회는 경험(평균 재직 기간 4.6 년)으로 간주됩니다.

Tonghua Golden-Horse Pharmaceutical Industry CoLtd 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd, Annual General Meeting, Jun 17, 2024

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Approves Board Elections

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd, Annual General Meeting, Jun 21, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.012 (vs CN¥0.005 in 3Q 2023)

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd to Report Q3, 2024 Results on Oct 21, 2024

Second quarter 2024 earnings released: EPS: CN¥0.003 (vs CN¥0.004 in 2Q 2023)

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd's (SZSE:000766) Popularity With Investors Is Under Threat From Overpricing

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd to Report First Half, 2024 Results on Aug 21, 2024

Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) Seems To Use Debt Quite Sensibly

New minor risk - Share price stability

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd, Annual General Meeting, Jun 17, 2024

Should You Be Adding Tonghua Golden-Horse Pharmaceutical Industry CoLtd (SZSE:000766) To Your Watchlist Today?

Full year 2023 earnings released: EPS: CN¥0.05 (vs CN¥0.03 in FY 2022)

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd to Report Q1, 2024 Results on Apr 23, 2024

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SZSE:000766) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.005 (vs CN¥0.005 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.004 (vs CN¥0.002 in 2Q 2022)

New minor risk - Share price stability

Now 23% undervalued

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd Approves Board Elections

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd to Report First Half, 2023 Results on Aug 21, 2023

Now 21% undervalued after recent price drop

Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd, Annual General Meeting, Jun 21, 2023

Now 22% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥0.03 (vs CN¥0.04 in FY 2021)

Now 20% undervalued after recent price drop

Now 21% undervalued

Now 20% undervalued

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.005 (vs CN¥0.007 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.002 (vs CN¥0.02 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.006 (vs CN¥0.004 in 1Q 2021)

High number of new and inexperienced directors

Full year 2021 earnings released: EPS: CN¥0.04 (vs CN¥0.37 loss in FY 2020)

Third quarter 2021 earnings released: CN¥0.007 loss per share (vs CN¥0.09 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.02 (vs CN¥0.033 loss in 2Q 2020)

Full year 2020 earnings released: CN¥0.37 loss per share (vs CN¥2.11 loss in FY 2019)

New 90-day high: CN¥4.26

New 90-day low: CN¥3.13

New 90-day low: CN¥3.56

Tibet Dechangtai Pharmaceutical Technology Co., Ltd. signed a share transfer agreement to acquire Lhasa Yongkang Medicine Co., Ltd. from Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (SZSE:000766) for CNY 5.1 million.

Third quarter earnings released

New 90-day low: CN¥3.87

New 90-day low: CN¥4.54

New 90-day low: CN¥4.62

New 90-day high - CN¥5.58

First half earnings released

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령